Alzheimer’s and Parkinson’s pipelines are rapidly expanding beyond amyloid and into next-generation mechanisms such as α-synuclein, neuroinflammation, and metabolic targets. Against the backdrop of a globally surging patient population, the […]

The past decade has transformed liquid biopsy, which was previously just an exciting concept, into a routine, commercially viable technology that is saving patients’ lives and transforming clinical trials. Uniting […]

With Novartis committing $750M to ProFound Therapeutics to discover new cardiovascular candidates, and Illumina acquiring SomaLogic for $425 to expand its proteomic capabilities just this year alone, the increasing recognition […]